- 26 ноября 2013, 17:10
- SeekingAlpha.com. Market Currents
- Isis Pharmaceuticals (ISIS) starts a Phase 1 study of ISIS-GSK3 in "a therapeutic area where there is a significant need for better therapies."
- The investigational drug "is designed to inhibit the production of an undisclosed target." (PR)
- The initiation of the study earns ISIS a $3M milestone payment from GlaxoSmithKline (GSK).
- ISIS +2.8% premarket
НОВОСТИ ПО ТЕМЕ